

MRC Holland launches two digital MLPA probe mixes

December 2022—MRC Holland released two assays, the Salsa digitalMLPA Probemix D006 Multiple Myeloma and Salsa digitalMLPA Probemix D007 Acute Lymphoblastic Leukemia.

The multiple myeloma panel detects copy number abnormalities on various chromosomal arms (1p, 1q, 13q, 17p) and in multiple-myeloma-associated genes. It also detects trisomies, hyper- and hypodiploidy, and the *BRAF V600E* mutation associated with multiple myeloma. The acute lymphoblastic leukemia panel detects gains and losses in 52 specific target genes and three chromosomal regions (5q, iAMP21, and PAR1) associated with ALL. It can be used to examine intragenic copy number abnormalities, aneuploidies, and whole chromosome gains, losses, and amplifications, as well as gross ploidy changes and intrachromosomal gene fusions.

The panels are based on the company's Salsa digitalMLPA technology, which merges multiplex ligation-dependent probe amplification with next-generation sequencing. Turnaround time is 48 to 72 hours using a DNA input of 20 ng per reaction. The products are for research use only.

[MRC Holland](#), +31 88 8657200